Vertex In The Vortex: More Cash, A Bigger Loss And The Departure Of A Key Executive
This article was originally published in The Pink Sheet Daily
The drug maker sells future milestone payments for its Hepatitis C drug, but loses its chief commercial officer and head of strategic development.
You may also be interested in...
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.